글로벌 뼈암 치료제 시장 – 2028년까지의 산업 동향 및 예측

시장 분석 및 통찰력: 글로벌 뼈암 약물 시장

뼈암 치료제 시장은 2021년부터 2028년까지의 예측 기간 동안 4.96%의 잠재적 시장 성장률을 기록할 것으로 예상됩니다. 노령 인구의 증가는 시장 성장을 가속화하는 중요한 요인입니다.

뼈암은 악성이며 뼈에 종양이나 암세포가 형성되어 발생합니다. 형성은 신체의 어느 뼈에서나 무작위로 발생할 수 있지만 주로 골반이나 팔과 다리의 긴 뼈에 영향을 미칩니다. 뼈암 환자는 뼈 통증, 부기로 인해 피로와 체중 감소를 경험할 수 있습니다.

전 세계적으로 뼈암 유병률 증가는 시장 성장을 촉진하고, 첨단 신규 표적 기반 치료법에 대한 수요도 증가하며, 전 세계적으로 약물의 가용성을 개발하거나 확대하기 위한 회사 간의 전략적 제휴가 증가하고, 유리한 환불 정책이 증가하고, 의료 지출이 증가하고, 시장 주요 참여자의 연구 개발 투자가 증가하고, 질병에 대한 인식이 높아지는 것은 뼈암 약물 시장 성장을 주도하는 주요 요인 중 일부입니다. 게다가, 의료 기기의 현대화와 기술적 진보가 증가하고 신흥 경제권에서 수요가 증가함에 따라 2021-2028년 예측 기간 동안 뼈암 약물 시장에 새로운 기회가 생길 것입니다.

그러나 일부 저소득 및 중소득 국가에서는 치료 및 진단에 드는 비용이 높고 뼈암에 대한 전문성과 지식이 부족한 것이 주요 제약 요소이며, 위에서 언급한 예측 기간 동안 뼈암 치료제 시장은 더욱 어려워질 것입니다.

This bone cancer drug market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis on the bone cancer drug market scenario contact Data bridge market research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Bone Cancer Drug Market Scope and Market Size

The bone cancer drug market is segmented on the basis of type, treatment, route of administration, distribution channel and end-users. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of type, the bone cancer drug market is segmented into multiple myeloma, osteosarcoma, chondrosarcoma and Ewing’s sarcoma.
• Based on treatment, the bone cancer drug market is segmented into targeted therapy, chemotherapy, radiation therapy and surgery. Targeted therapy has been further segmented into imatinib and denosumab. Chemotherapy has been further segmented into doxorubicin, cisplatin, etoposide, ifosfamide, cyclophosphamide, methotrexate and vincristine. Radiation therapy has been further segmented into intensity-modulated radiation therapy, proton-beam radiation and extracorporeal radiation. Surgery has been further segmented into amputation, limb-salvage surgery, reconstructive surgery, cryosurgery and curettage.
• Based on route of administration, the bone cancer drug market is segmented into oral and injectable.
• Based on distribution channel, the bone cancer drug market is segmented into online pharmacy, direct tenders, retailers and others.
• The bone cancer drug market is also segmented on the basis of end-users into hospitals, homecare, specialty clinics and others.

Bone Cancer Drug Market Country Level Analysis

The bone cancer drug market is analysed and market size information is provided by country, type, treatment, route of administration, distribution channel and end-users as referenced above.

The countries covered in the bone cancer drug market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America dominates the bone cancer drug market due to rise in the demand for advanced novel-targeted based therapies and rise in the strategic alliances between the companies to develop or to expand the availability of drugs in this region.

The country section of the bone cancer drug market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The bone cancer drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Bone Cancer Drug Market Share Analysis

The bone cancer drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to bone cancer drug market.

뼈암 약물 시장 보고서에서 다루는 주요 기업은 Advaxis, Inc., Cellectar Biosciences, Inc., OPKO Health, Inc., Pfizer Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, Debiopharm Group, Merck & Co., Inc., Bayer AG, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited, CELGENE CORPORATION, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd., AstraZeneca 및 Sanofi 등 국내 및 글로벌 기업입니다. 골관절염 통증 관리 치료 점유율 데이터는 글로벌, 북미, 남미, 유럽, 아시아 태평양(APAC) 및 중동 및 아프리카(MEA)에 대해 개별적으로 제공됩니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 개별적으로 제공합니다.

SKU-44826